ABSTRACT
Mechanical ventilation of the newborn infant has increased neonatal survival. However, this increased survival has come at the expense of increased morbidity, in the form of bronchopulmonary dysplasia, and at the cost of an expensive technology. Continuous positive airway pressure (CPAP) is accepted as conferring clinical benefit in supporting the recently extubated preterm infant and in the management of apnea of prematurity. Attention is now being drawn to physiologic and clinical evidence to support CPAP use, with or without early surfactant, as a primary treatment of hyaline membrane disease. The purpose of this review is to explore these proposed benefits of non invasive ventilation and place them in the context of current clinical evidence.
Subject(s)
Bronchopulmonary Dysplasia/physiopathology , Continuous Positive Airway Pressure/instrumentation , Equipment Design , Functional Residual Capacity , Humans , Infant, Newborn , Intermittent Positive-Pressure Ventilation , Respiration, Artificial/methodsABSTRACT
Se realizó un estudio ultraesructural e histoquímico del efecto que ejerce el 4-metil umbelliferil ß-D-xilósido (4MUX) sobre la pared de la aorta de embriones de pollo del estadío 36. Se inocularon huevos fértiles de gallina white legorn a los 2.5 días de desarrollo (estadío 17) con 0.1 ml de 4MUX. Sus efectos se observaron con técnicas de microscopía electrónica de barrido e histoquímicas. Se ha puesto de manifiesto que el 4MUX interfiere en el desarrollo normal de la aorta. Causando alteraciones en la distribución de elastina, colágeno y GAGs en los espacios intercelulares